Page 5 - Wockhardt

Wockhardt freezes at 5% lower circuit post weak operating performance in Q1

Company reported negative EBITDA for the quarter at Rs 49 crores as against positive EBITDA of Rs 56 crores in Q1FY20.

Wockhardt reports net profit at Rs 760 cr for June qtr on exceptional items

Drug firm Wockhardt on Saturday reported a consolidated net profit of Rs 759.75 crore for June quarter mainly on account of exceptionalitems in connection with the transfer of a business comprising 62 products and Baddi facility toDr Reddy's Laboratories. The company had posted a net loss of Rs 36.88 crore for April-June 2019-20, Wockhardt said in a filing to BSE. Total income stood at Rs 606.22 crore in the quarter under review. It was Rs 733.66 crore in the year-ago period, the filing added. Wockhardt launchednew chemical entity (NCE) during the quarterin the Indian pharma market. Products have been launched under the tablet and injection category under the brand name 'Emrock O and Emrock', the filing said. The focus on strategic R&D initiatives of the company in the global arena continued to remain one of the key priorities,itadded. It said that divestment of business undertaking to Dr Reddy's Laboratories was accomplished during the quarter and Rs 1,483 crore has been received

Wockhardt to supply Covid-19 vaccines to UK govt; stock soars 27% in 3 days

The UK government has also reserved one fill-and-finish production line at a Wockhardt subsidiary in Wrexham, Wales for its exclusive use for the next 18 months to secure supply

Wockhardt plans to supply Covid-19 vaccines to UK; shares jump 10%

The firm has reserved fill-and-finish capacity - the final manufacturing step of putting vaccines into vials or syringes and packaging them - as part of the agreement, it said

Covid-19 vaccine pact with Wockhardt will guarantee supply: UK govt

"Ensuring the UK has the capability to research, develop and manufacture a safe and effective vaccine is critical in our fight against coronavirus," said UK Business Secretary Alok Sharma

A glimmer of hope but...

...dexamethasone's positive effect on patients with severe Covid-19 infection and no effect on mild ones imply that it will not be used on a large scale

Revised Wockhardt deal boosts prospects of Dr Reddy's India business

The company, according to its new strategy, is focusing on growing its India-based branded products

Dr Reddy's closes Wockhardt branded generics deal on modified terms

Under new terms, DRL to hold back Rs 300 crore and release it if the revenue from sale of the products forming part of the business undertaking during the 12 months post-closing exceeds Rs 480 cr

Covid-19 crisis prompts India to look for global partners in health care

Medical devices industry has potential to attract Rs 70,000 crore in 5 years

Antiviral drugs see demand surge in India, but segment declines 5.5%

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Ind-Ra places Wockhardt on rating watch evolving with negative outlook

As per the management, said Ind-Ra, the deal is in line with Wockhardt's strategic plan to shift from acute therapeutic areas to more chronic businesses such as anti-diabetes, central nervous system e

Diabetes to be our focus in India, US: Wockhardt's Habil Khorakiwala

Wockhardt is present in emerging markets like Mexico, Brazil with insulins

Market Wrap, Feb 13: Sensex slips 106 pts, Nifty ends at 12,175

Sectorally, Nifty Private Bank index fell around 1.4 per cent to 17,083 levels. Nifty Bank slid 0.8 per cent to 31,230 points. On the upside, pharma and IT stocks advanced the most

Wockhardt tanks 5% after it sells domestic branded ops to Dr Reddy's Labs

The deal, which could fetch a consideration amount of Rs 1,850 crore, is expected to close in the first quarter of financial year 2020-21, Wockhardt added.

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

Dr Reddy's to acquire part of Wockhardt's India business for Rs 1,850 crore

The agreement comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, and dermatology.

Market Wrap, Feb 11: Sensex snaps 2-day losing streak, rises 237 pts

In the intra-day deals, the Sensex and Nifty50 hit a high of 41,444.34 and 12,172.30 level, respectively

Wockhardt hits over 7-month high; stock zooms 63% in one month

The stock was trading higher for the third straight day, surging 10 per cent, on the BSE on Tuesday. It was its highest level since June 27, 2019.

Wockhardt becomes first Indian company to get nod for novel antibiotics

While multinational companies have launched new antibiotics in India, there have been no new launches in the past 15 years in this category

Top headlines: SC dismisses AGR review petitions, ED summons AirAsia execs

The Enforcement Directorate (ED) has summoned senior executives of AirAsia including CEO Tony Fernandes for questioning in connection with a money laundering case